Miguel Angel Alvarez-Mon1,2,3, Ana Maria Gomez-Lahoz2, Arantxa Orozco4, Guillermo Lahera2,4,5, M Dolores Sosa-Reina2, David Diaz2, Agustin Albillos2,6,7,8, Javier Quintero3,9, Patricio Molero1, Jorge Monserrat2, Melchor Alvarez-Mon2,7,8,10. 1. Department of Psychiatry and Medical Psychology, University Clinic of Navarra, Pamplona, Spain. 2. Department of Medicine and Medical Specialities, University of Alcala, Alcala de Henares, Spain. 3. Department of Psychiatry and Mental Health, Hospital Universitario Infanta Leonor, Madrid, Spain. 4. Department of Psychiatry, University Hospital "Principe de Asturias", Alcalá de Henares, Spain. 5. CIBERSAM (Biomedical Research Networking Centre in Mental Health), Madrid, Spain. 6. Department of Gastroenterology, University Hospital Ramon y Cajal, Madrid, Spain. 7. Institute Ramon y Cajal for Health Research (IRYCIS), Madrid, Spain. 8. Biomedical Institute for Liver and Gut Diseases (CIBEREHD), Madrid, Spain. 9. Department of Legal and Psychiatry, Complutense University, Madrid, Spain. 10. Service of Internal Medicine and Rheumatology, Autoimmune Diseases University Hospital "Principe de Asturias", Madrid, Spain.
Abstract
Background: Major Depressive Disorder (MDD) is associated with both proinflammatory and adaptive immune response abnormalities. Regulatory T lymphocytes (Tregs), a subtype of CD4+ T cells, are relevant for maintaining immune-inflammatory system homeostasis and control of inflammation such as the kind potentially induced by the interactions between the intestinal microbiome and gut mucosa. We investigated the Treg population and its distribution along their stages of differentiation/activation, as well as its function in MDD patients without concomitant diseases. We also studied the potential association between Treg alterations, intestinal barrier damage, and bacterial translocation. Methods: 30 MDD patients and 20 healthy controls were studied. The levels of circulating CD25FoxP3+ Tregs and their distribution on the naïve (TN), effector (TE), central (TCM), and effector memory(TEM) differentiation/activation stages were analyzed using polychromatic flow cytometry. Chemokine receptors (CCR) 2, 5, and 6, and the intracytoplasmic IL-10 expression by the Tregs were also analyzed. The serum IL-10 was measured using Luminex. The serum levels of zonulin and the intestinal fatty acid-binding protein (I-FABP), both markers of gut barrier function, and the LPS-binding protein (LBP), a marker of bacterial translocation, were measured using an enzyme-linked immunosorbent assay. Results: MDD patients had increased number of circulating Tregs cells with enhanced number of Tregs at the TN, TE, TCM, and TEM stages. The percentage of Tregs cells at TN stage was significantly higher in MDD patients. The percentage of Tregs that expressed CCR2 and CCR6 was increased as well as those expressing IL-10. MDD patients had significantly increased levels of circulating I-FABP and LBP. MDD patients with high LBP levels had a significant reduction in the number of circulating Tregs compared to normal-LBP MDD patients. Conclusions: MDD patients showed an expansion of circulating Tregs and their CD25highFoxP3+ and CD25lowFoxP3+ subsets throughout the different stages of CD4+ T lymphocyte differentiation/activation. Tregs also showed an increased frequency of cells expressing CCR6 and CCR2. IL-10 Treg production was also enhanced in MDD patients that concurrently had increased serum IL-10 levels. However, this Treg expansion was blunted in MDD patients with gut barrier damage and increased bacterial translocation.
Background: Major Depressive Disorder (MDD) is associated with both proinflammatory and adaptive immune response abnormalities. Regulatory T lymphocytes (Tregs), a subtype of CD4+ T cells, are relevant for maintaining immune-inflammatory system homeostasis and control of inflammation such as the kind potentially induced by the interactions between the intestinal microbiome and gut mucosa. We investigated the Treg population and its distribution along their stages of differentiation/activation, as well as its function in MDDpatients without concomitant diseases. We also studied the potential association between Treg alterations, intestinal barrier damage, and bacterial translocation. Methods: 30 MDDpatients and 20 healthy controls were studied. The levels of circulating CD25FoxP3+ Tregs and their distribution on the naïve (TN), effector (TE), central (TCM), and effector memory(TEM) differentiation/activation stages were analyzed using polychromatic flow cytometry. Chemokine receptors (CCR) 2, 5, and 6, and the intracytoplasmic IL-10 expression by the Tregs were also analyzed. The serum IL-10 was measured using Luminex. The serum levels of zonulin and the intestinal fatty acid-binding protein (I-FABP), both markers of gut barrier function, and the LPS-binding protein (LBP), a marker of bacterial translocation, were measured using an enzyme-linked immunosorbent assay. Results:MDDpatients had increased number of circulating Tregs cells with enhanced number of Tregs at the TN, TE, TCM, and TEM stages. The percentage of Tregs cells at TN stage was significantly higher in MDDpatients. The percentage of Tregs that expressed CCR2 and CCR6 was increased as well as those expressing IL-10. MDDpatients had significantly increased levels of circulating I-FABP and LBP. MDDpatients with high LBP levels had a significant reduction in the number of circulating Tregs compared to normal-LBPMDDpatients. Conclusions: MDDpatients showed an expansion of circulating Tregs and their CD25highFoxP3+ and CD25lowFoxP3+ subsets throughout the different stages of CD4+ T lymphocyte differentiation/activation. Tregs also showed an increased frequency of cells expressing CCR6 and CCR2. IL-10Treg production was also enhanced in MDDpatients that concurrently had increased serum IL-10 levels. However, this Treg expansion was blunted in MDDpatients with gut barrier damage and increased bacterial translocation.
Authors: D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar Journal: J Clin Psychiatry Date: 1998 Impact factor: 4.384
Authors: L Ohlsson; A Gustafsson; E Lavant; K Suneson; L Brundin; Å Westrin; L Ljunggren; D Lindqvist Journal: Acta Psychiatr Scand Date: 2018-11-01 Impact factor: 6.392
Authors: Miguel A Alvarez-Mon; Miguel A Ortega; Cielo García-Montero; Oscar Fraile-Martinez; Guillermo Lahera; Jorge Monserrat; Ana M Gomez-Lahoz; Patricio Molero; Luis Gutierrez-Rojas; Roberto Rodriguez-Jimenez; Javier Quintero; Melchor Alvarez-Mon Journal: J Int Med Res Date: 2022-05 Impact factor: 1.573
Authors: Cielo García-Montero; Miguel A Ortega; Miguel Angel Alvarez-Mon; Oscar Fraile-Martinez; Adoración Romero-Bazán; Guillermo Lahera; José Manuel Montes-Rodríguez; Rosa M Molina-Ruiz; Fernando Mora; Roberto Rodriguez-Jimenez; Javier Quintero; Melchor Álvarez-Mon Journal: Nutrients Date: 2022-03-06 Impact factor: 5.717
Authors: Miguel A Ortega; Óscar Fraile-Martínez; Cielo García-Montero; Miguel Angel Alvarez-Mon; Guillermo Lahera; Jorge Monserrat; Maria Llavero-Valero; Luis Gutiérrez-Rojas; Rosa Molina; Roberto Rodríguez-Jimenez; Javier Quintero; Melchor Alvarez De Mon Journal: Nutrients Date: 2022-07-28 Impact factor: 6.706
Authors: Oscar Fraile-Martinez; Miguel A Alvarez-Mon; Cielo Garcia-Montero; Leonel Pekarek; Luis G Guijarro; Guillermo Lahera; Miguel A Saez; Jorge Monserrat; Domitila Motogo; Javier Quintero; Melchor Alvarez-Mon; Miguel A Ortega Journal: Front Oncol Date: 2022-09-16 Impact factor: 5.738
Authors: Miguel Angel Alvarez-Mon; Ana Maria Gómez-Lahoz; Arancha Orozco; Guillermo Lahera; David Diaz; Miguel A Ortega; Agustin Albillos; Javier Quintero; Enrique Aubá; Jorge Monserrat; Melchor Alvarez-Mon Journal: J Pers Med Date: 2021-03-19
Authors: Miguel A Ortega; Miguel Angel Alvarez-Mon; Cielo García-Montero; Oscar Fraile-Martinez; Luis G Guijarro; Guillermo Lahera; Jorge Monserrat; Paula Valls; Fernando Mora; Roberto Rodríguez-Jiménez; Javier Quintero; Melchor Álvarez-Mon Journal: Metabolites Date: 2022-01-08